Christopher Haqq
Executive Vice President, Head of R&D and Chief Medical Officer · Elicio Therapeutics, Inc.
Individual
- 2024
- Jul 17, 2026
- 3
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Christopher Haqq's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- BERKSHIRE HATHAWAY INC - $473.67M in DVA purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $430.69M in PBLS purchases and sales in the last 12 months
- Fairmount Funds Management LLC - $399.66M in SYRE purchases and sales in the last 12 months
- Paul R. Vigano - $371.84M in AVAH purchases and sales in the last 12 months
- Robert M. Williams Jr. - $371.84M in AVAH purchases and sales in the last 12 months
- August J. Troendle - $358.45M in MEDP purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher Haqq?
Christopher Haqq is a corporate insider, tracked as Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics, Inc. (ELTX). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Christopher Haqq submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
